KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBT Margin (2020 - 2023)

Historic EBT Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 529.49%.

  • AbCellera Biologics' EBT Margin fell 3836900.0% to 529.49% in Q4 2023 from the same period last year, while for Dec 2023 it was 457.66%, marking a year-over-year decrease of 5069200.0%. This contributed to the annual value of 695.02% for FY2024, which is 2373500.0% down from last year.
  • As of Q4 2023, AbCellera Biologics' EBT Margin stood at 529.49%, which was down 3836900.0% from 595.18% recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' EBT Margin peaked at 79.65% during Q1 2021, and registered a low of 595.18% during Q3 2023.
  • Moreover, its 4-year median value for EBT Margin was 21.88% (2022), whereas its average is 137.27%.
  • In the last 5 years, AbCellera Biologics' EBT Margin skyrocketed by 4993300bps in 2022 and then crashed by -6411300bps in 2023.
  • AbCellera Biologics' EBT Margin (Quarter) stood at 77.52% in 2020, then dropped by -22bps to 60.8% in 2021, then crashed by -340bps to 145.8% in 2022, then crashed by -263bps to 529.49% in 2023.
  • Its EBT Margin stands at 529.49% for Q4 2023, versus 595.18% for Q3 2023 and 377.92% for Q2 2023.